| abstract |
The present invention is concerned with compounds of formula 1: ##STR1## wherein R 1 is straight or branched alkyl having 1-4 C-atoms, halogen or cyano; n n has the value 0-1; n R 2 is hydrogen, (1-6 C)alkyl, (3-6 C)alkenyl, (3-6 C)alkenyl, (3-6 C)cycloalkyl, (3-6 C)cycloalkyl-(1-4 C) alkyl, phenyl, phenyl-(1-3 C)alkyl, COOR 6 , COR 6 , CONR 6 R 7 or SO 2 --R 6 , wherein R 6 and R 7 independently of each other are hydrogen, (1-6 C)alkyl, (3-6 C)cycloalkyl, phenyl or phenyl-(1-4 C)alkyl, wherein the benzene ring is optionally substituted with a methyl group or a halogen atom, with the proviso that R 6 is not hydrogen when R 2 is a group COOR 6 or SO 2 R 6 ; n R 3 is hydrogen, straight or branched (1-6 C)alkyl or a phenyl-(1-3 C)alkyl group optionally substituted in the benzene ring; and n A is a group of formula 2 or 3 ##STR2## wherein one of the groups R 8 , R 9 and R 10 is hydrogen, (1-C)alkyl, (3-6 C)cycloalkyl, (3-4 C)alkenyl or (3-4 C)alkynyl and the two other groups, independently of each other, are hydrogen or (1-4 C)alkyl, and the pharmacologically acceptable acid addition salts thereof, which are pharmaceutically useful as strong and selective antagonists of "neuronal" 5-hydroxy tryptamine (5-HT) receptors. |